The randomised clinical trial and the hazard ratio - medical research's Emperor's New Clothes?

0Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

As the enthusiasm for individualized treatment and targeted therapies continues to gain momentum, it seems timely to re-assess whether our current research tools are fit for purpose. Randomized Clinical Trials compare groups of patients, the Hazard Ratio is a 'group summary statistic', and modeling shows that the same Hazard Ratio score could result from a number of scenarios. Thus the current tools do not provide definitive information as to how to treat an individual patient. We therefore need to concentrate on the use of predictive factor analyses to identify the characteristics of subgroups of patients who respond to specific treatments. © 2014 Stephens and Stewart; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Stephens, R., & Stewart, D. (2014, April 14). The randomised clinical trial and the hazard ratio - medical research’s Emperor’s New Clothes? BMC Cancer. BioMed Central Ltd. https://doi.org/10.1186/1471-2407-14-260

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free